Variability of Peripheral Pulse Wave Velocity in Patients With Diabetes Mellitus Type 2 During Orthostatic Challenge

Svačinová, Jana; Hrusková, J; Jakubík, Juraj; Budinskaya, Ksenia; Hidegová, Simona; Fabšík, Martin; Sieglová, Helena; Kaščáková, Zuzana; Novák, Jan; Nováková, Zuzana

doi:10.33549/physiolres.934594

Cited by 8 publications

(4 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The peripheral PWV (baPWV), represented by volume waveforms for the brachium and ankle, was measured using an automated waveform analyzer (Colin VP-1000; Omron Healthcare, Kyoto, Japan), as previously described 23 . In brief, the analyzer recorded the electrocardiogram, phonocardiogram, and three pulse waves from the brachial and dorsalis pedis arteries.…”

Section: Methodsmentioning

confidence: 99%

Curcumin Extract Diminishes Atherogenic Risk in Type 2 Diabetes Mellitus Patients With Obesity

Yaikwawong,

Jansarikit,

Jirawatnotai

et al. 2024

Preprint

View full text Add to dashboard Cite

BackgroundCurcumin, which is derived from turmeric root and is widely utilized in Asian cuisines, exhibits notable anti-inflammatory effects. Its consumption has proven beneficial in alleviating inflammation-related disorders such as ulcerative colitis, rheumatoid arthritis, and esophagitis. These anti-inflammatory properties might also provide advantages in reducing cardiovascular complications, such as atherosclerosis, which is particularly prevalent among diabetic individuals. This study aimed to evaluate the efficacy of curcumin in decreasing the risk of atherogenesis in obese patients with type 2 diabetes.MethodsThe study employed a rigorous randomized, double-blind, placebo-controlled trial design with 265 participants who were diagnosed with type 2 diabetes. Subjects were randomly assigned to receive either curcumin capsules or a placebo over 12 months. The key metrics used to assess atherogenic risk reduction included pulse wave velocity and various metabolic profiles. These profiles included low-density lipoprotein cholesterol, small dense low-density lipoprotein cholesterol, apolipoprotein B, triglyceride to high-density lipoprotein ratio, uric acid, waist circumference, total body fat, and visceral fat. Measurements were recorded at baseline and at 3-, 6-, 9-, and 12-month intervals throughout the treatment phase.ResultsAfter 12 months, participants receiving curcumin exhibited a significant reduction in pulse wave velocity (P < 0.001). Furthermore, this group also showed significantly reduced levels of various cardiometabolic risk biomarkers. These included low-density lipoprotein cholesterol, small dense low-density lipoprotein cholesterol, apolipoprotein B, the triglyceride to high-density lipoprotein ratio, uric acid, waist circumference, and total body fat, all withPvalues less than 0.001. Additionally, visceral fat levels were reduced, with aPvalue of 0.01. Markers of inflammation (high-sensitivity C-reactive protein, interleukin-1 beta, interleukin-6, and tumor necrosis factor-alpha) were also significantly lower in the curcumin group than in the placebo group, withPvalues less than 0.001.ConclusionsThe 12-month administration of curcumin to patients with type 2 diabetes and obesity significantly reduced pulse wave velocity and improved cardiometabolic risk profiles. It also demonstrated substantial anti-inflammatory effects with minimal adverse outcomes. These findings suggest that curcumin treatment may effectively reduce atherogenic risks in obese patients with type 2 diabetes.Trial registrationThai Clinical Trials Registry:TCTR20140303003Clinical PerspectiveWhat Is New?Individual patient data from randomized trials of curcumin extract versus placebo, spanning a 12-month period and including a rather large sample size (n=227), are analyzed collectively.Curcumin extract use resulted in a significant reduction in pulse wave velocity and showed a significant improvement in cardiometabolic risk profiles.What Are the Clinical Implications?The efficacy and safety data from randomized clinical trials supports the use of curcumin extract over placebo for mitigating inflammation and improving cardiometabolic risk factors.Curcumin supplementation shows promise in protecting against atherosclerosis and related cardiovascular diseases in patients with T2DM and obesity.

show abstract

Section: Methodsmentioning

confidence: 99%

Curcumin Extract Diminishes Atherogenic Risk in Type 2 Diabetes Mellitus Patients With Obesity

Yaikwawong,

Jansarikit,

Jirawatnotai

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…All the measurements were calibrated using blood pressure values obtained from the oscillometric automated measurement on the ipsilateral brachial artery (Omron HEM, 907). In addition, variability of PWV (PWV V ) was measured in each respondent [ 14 ].…”

Section: Methodsmentioning

confidence: 99%

Changes in Nutritional State and Cardiovascular Parameters in Alimentary Obese Children after a Month-Long Stay in Children’s Treatment Center

et al. 2022

View full text Add to dashboard Cite

Childhood and adolescent obesity has become an important public health issue, as it leads to higher risk of cardio–metabolic, orthopedic, and psychological comorbidities. The aim of this study was to evaluate the changes in nutritional state and cardiovascular system parameters in obese children. Sixty respondents aged 9–17 years with alimentary obesity participated in this research. Anthropometric parameters (body weight (BWT), body mass index (BMI), percentage of body fat (%), waist and hip circumference (WC and HC), waist–hip ratio (WHR)) and cardiovascular parameters (systolic and diastolic blood pressure (SP and DP), cardio-ankle vascular index (CAVI), ankle-brachial index (ABI), pulse wave velocity and its variability (PWV and PWVV), and parameters of pulse wave analysis) were measured. Every respondent went through two sets of measurements, the first (I.) after their admission to the children’s hospital and the second (II.) at the end of their one-month-long therapeutic stay. Statistically significant differences between measurements I. and II. were observed in the following parameters: BWT (p < 0.01), BMI (p < 0.01), WC (p < 0.01), HC (p < 0.01), DP (p < 0.01), PWV (p < 0.05), and ABI (p < 0.01). The results of this study show that obesity has a mostly negative impact on the cardiovascular health of affected children, with likely negative results in their adulthood.

show abstract

“…○ Catheters can be pressure tip (preferred) or fluid filled (acceptable); fluid-filled catheters require due care with respect to calibration. 11 ○ Due to PWV beat-to-beat variability, 12 at least 10 heartbeats must be recorded. ○ See the Practical Considerations section for further details.…”

Section: Reference Standards Choice Of Reference Standardmentioning

confidence: 99%

2024 Recommendations for Validation of Noninvasive Arterial Pulse Wave Velocity Measurement Devices

Spronck,

Terentes-Printzios,

Avolio

et al. 2024

Hypertension

View full text Add to dashboard Cite

BACKGROUND: Arterial stiffness, as measured by arterial pulse wave velocity (PWV), is an established biomarker for cardiovascular risk and target-organ damage in individuals with hypertension. With the emergence of new devices for assessing PWV, it has become evident that some of these devices yield results that display significant discrepancies compared with previous devices. This discrepancy underscores the importance of comprehensive validation procedures and the need for international recommendations. METHODS: A stepwise approach utilizing the modified Delphi technique, with the involvement of key scientific societies dedicated to arterial stiffness research worldwide, was adopted to formulate, through a multidisciplinary vision, a shared approach to the validation of noninvasive arterial PWV measurement devices. RESULTS: A set of recommendations has been developed, which aim to provide guidance to clinicians, researchers, and device manufacturers regarding the validation of new PWV measurement devices. The intention behind these recommendations is to ensure that the validation process can be conducted in a rigorous and consistent manner and to promote standardization and harmonization among PWV devices, thereby facilitating their widespread adoption in clinical practice. CONCLUSIONS: It is hoped that these recommendations will encourage both users and developers of PWV measurement devices to critically evaluate and validate their technologies, ultimately leading to improved consistency and comparability of results. This, in turn, will enhance the clinical utility of PWV as a valuable tool for assessing arterial stiffness and informing cardiovascular risk stratification and management in individuals with hypertension.

show abstract

Variability of Peripheral Pulse Wave Velocity in Patients With Diabetes Mellitus Type 2 During Orthostatic Challenge

Cited by 8 publications

References 42 publications

Curcumin Extract Diminishes Atherogenic Risk in Type 2 Diabetes Mellitus Patients With Obesity

Curcumin Extract Diminishes Atherogenic Risk in Type 2 Diabetes Mellitus Patients With Obesity

Changes in Nutritional State and Cardiovascular Parameters in Alimentary Obese Children after a Month-Long Stay in Children’s Treatment Center

2024 Recommendations for Validation of Noninvasive Arterial Pulse Wave Velocity Measurement Devices

Contact Info

Product

Resources

About